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'It's not about money, it's about my health': Determinants of participation and
adherence among women in an HIV-HSV2 prevention trial in Johannesburg,
South Africa
Abstract
High levels of adherence in clinical trials are essential for producing accurate intervention efficacy
estimates. Adherence to clinical trial products and procedures is dependent on the motivations that drive
participants. Data are presented to document reasons for trial participation and adherence to daily
aciclovir for HSV-2 and HIV-1 genital shedding suppression among 300 HIV-1/HSV-2 seropositive women
in South Africa. In-depth interviews after exit from the trial with 31 randomly selected women stratified by
age and time since HIV diagnosis confirmed high levels of adherence measured during the trial. Main
reasons for trial participation were related to seeking high-quality health care, which explains high levels
of adherence in both study arms. Concerns that women would abuse reimbursements, fabricate data, and
share or dump pills were not corroborated. Altruism is not a primary motivator in these settings where
access to quality services is an issue. This study provides further evidence that good adherence of daily
medication is possible in developing countries, particularly where study activities resonate with
participants or fill an unmet need.
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Abstract: High levels of adherence in clinical trials are essential for producing accurate
intervention efficacy estimates. Adherence to clinical trial products and procedures is dependent
on the motivations that drive participants. Data are presented to document reasons for trial
participation and adherence to daily aciclovir for HSV-2 and HIV-1 genital shedding suppression among 300 HIV-1/HSV-2 seropositive women in South Africa. In-depth interviews after
exit from the trial with 31 randomly selected women stratified by age and time since HIV
diagnosis confirmed high levels of adherence measured during the trial. Main reasons for trial
participation were related to seeking high-quality health care, which explains high levels of
adherence in both study arms. Concerns that women would abuse reimbursements, fabricate
data, and share or dump pills were not corroborated. Altruism is not a primary motivator in
these settings where access to quality services is an issue. This study provides further evidence
that good adherence of daily medication is possible in developing countries, particularly where
study activities resonate with participants or fill an unmet need.
Keywords: adherence, trial, HIV prevention, South Africa

Much of the limited efficacy of recent biomedical HIV prevention trials has been
attributed to suboptimal adherence among trial participants.1 Concerns have been
raised about participation in clinical trials being driven by reimbursement and that
pill dumping or sharing might be rampant in communities underserved by the formal
health sector. Such motivations for participation might negatively impact on study
adherence. Little research has been conducted to investigate the motivation driving
participants to take part in HIV prevention, as opposed to HIV treatment research trials
in low and middle income countries, and the impact this may have on trial adherence
and the validity of trial findings.
In this scant literature, altruism and access to personal health and behavioral benefits
have been recorded as the dominant reasons for participation in trials.2–4 Compensation
was noted as important among Kenyan participants in HIV/AIDS trials5 and among
vaccine trial participants in the US, Canada, and the Netherlands, although it was not
one of the main reasons for participation.2 Gender differences for trial participation
have been found, with women more likely than men to participate in trials for a broader
range of reasons, including access to protection, services, or compensation.2 In lower
and middle income countries there are particular concerns that compensation may
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drive trial participation and that this motivation may have
negative consequences for adherence.
The results of clinical trials for HIV prevention are
dependent on high levels of adherence, which has proven
problematic for a number of prevention strategies tested thus
far.6 There are three components to adherence in such trials:
(1) adherence to study visits as a prerequisite for product/
intervention adherence; (2) adherence to specific products/
interventions being tested within the trial; and (3) adherence
to additional practices required by the protocol (eg, the use of
condoms, avoidance of vaginal douching, abstinence, etc).
Measurement of adherence is challenging. Traditionally
product adherence has been measured through pill count and
self-report. Biomedical markers are increasingly being used
to monitor product adherence,7 but behavioral adherence
continues to rely on self-reported data. Such data has inherent
limitations associated with lack of participant cooperation,
problems with recall, and social desirability bias.8
In this study we examined reasons for trial participation
and the influence of this on subsequent adherence to study
drug and procedures among female trial participants in
Johannesburg, South Africa. Participants were HIV-HSV-2
co-infected women not yet eligible for anti-retroviral therapy
(ART) who were enrolled in a randomized, double-blinded,
placebo-controlled trial to examine the efficacy of twice daily
HSV-2 suppressive therapy with aciclovir in reducing HIV
transmissibility.9 Through this study we hope to confirm high
levels of trial adherence and how reasons for participation
might influence this. This information may be useful in the
design of future trials of HIV prevention interventions.

Methods
Study participants
Between April 2005 and April 2006, 300 HSV-2 and HIV
seropositive women were enrolled in a trial and randomized
to receive aciclovir 400 mg one tablet twice daily (n = 152)
or matching placebo (n = 148), and followed up at monthly
intervals for 3 months. Women had a mean age of 32 years
and a 1 year median time since HIV diagnosis, and were
compensated ZAR150 (approximately US$20) for each study
visit. Trial outcomes have been reported elsewhere.9
In the current study, a 10% random subsample of trial
participants from both study arms (n = 31) was recruited
according to three criteria: age (women were selected from
the 18–30 years and 31–60 years age groups); duration of
HIV infection (whether women were aware of their status
since #1 year or .1 year); and willingness to participate.
Once trial exit visits were completed, contact information
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collected during the trial was used to establish interest in
participating in an additional study visit and to set up interview times with participants. Appointments were made for
women to visit the clinic at a time suitable for them. At this
visit, the objectives of the in-depth interview (IDI) visit were
further explained and women provided written consent for
their participation in the interview, as well as permission for
their discussion to be tape recorded. Women were compensated ZAR50 (approximately US$7) for their participation.

Trial procedures and quantitative
data collection
During the trial, participants were seen at monthly clinic
visits (visit interval 30–35 days) for a total of three visits,
when drug packs were returned for pill count, a new supply
of drugs dispensed, and data on self-reported adherence
collected. At each visit, participants received adherence
counseling which included instructions for study drug use,
storage, and handling of missed doses.
All participants received pre- and post-test sexually
transmitted infection (STI)/HIV counseling, regular risk
reduction counseling, free condoms, treatment of STIs, and
referral to local HIV treatment centers. All participants with
symptoms of genital ulcers received presumptive treatment
for genital herpes with aciclovir for 5 days, irrespective of
study arm, in addition to the standard antimicrobial regimen
of syndromic management. As required by the study protocol,
participants were counseled to avoid vaginal cleansing and
unprotected sexual intercourse for 72 hours before their next
clinic visit when genital samples were collected. Where
sex was unavoidable, participants were encouraged to use
a condom in order to avoid contamination of samples with
semen. Free condoms were provided.

Qualitative data collection
Interviews were conducted face-to-face with a single female
interviewer in local South African languages. The interviews
lasted approximately 90 minutes and were tape-recorded.
The interviewer used a semi-structured interview topic
guide in which women’s reasons for participation and their
adherence to various aspects of the study were examined.
The interview topic guide was developed in English and
reviewed by the interviewer and study investigators to ensure
that meaning in local African languages was clear and that
there was agreement on correct terminology for discussions.
To ensure that participants were comfortable discussing the
issue of trial adherence, data collection was conducted after
each participant’s exit visit from the trial, once adherence
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measures had already been calculated and participants were
no longer on treatment. Additionally, women were assured of
confidentiality and explicitly informed that their adherence
issues would not be discussed with staff from the trial.
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Qualitative data analysis
Recorded interviews were independently translated and
transcribed into English. One of the investigators (CM) read
through all transcripts to identify major themes. Thereafter a
coding frame was constructed using Atlas.ti (v 5.2; Scientific
Software Development, Berlin, Germany) and a line-by-line
review of transcripts was conducted. Quotes were allocated
to codes using a framework analysis approach. 10 Text
corresponding to each of the themes was grouped together
and reviewed. Analysis continued as an iterative process
through discussions and refining of the major themes.
Sub-themes were then established using a method of constant
comparison11 to break down higher-level codes (themes)
into smaller categories within the framework. Quotes were
selected for inclusion in the paper if they reflected dominant
attitudes and actions or were good illustrations of counter
normative behavior.

Ethical approval
The Human Research Ethics Committee (HREC) of the
University of the Witwatersrand and the ethics review board
of the London School of Hygiene and Tropical Medicine
approved the trial. The trial was registered with the South
African Department of Health national register of clinical
trials (DoH-27-0207-1376). The qualitative interview was
approved by the HREC as an auxiliary study to the trial
(Reference: 061003).

Participation and adherence in women with HIV

in the trial noted that the opportunity to establish whether they
were HIV and HSV-2 seropositive were important motivators
in their trial participation. These women had not necessarily
experienced symptoms of either disease prior to screening and
enrolment into the trial but were aware of the high prevalence
of both in local communities, either prior to engagement with
trial staff or after participation in screening health talks, and
wanted to be sure of their own serostatus.
The reasons that I came here is that they told us that they
are going to check us first if we do not have herpes. Then
I thought it is better that I come because herpes is something
that is not nice to have. The other thing is the sooner they
find out that I have herpes, the sooner they will treat it.
It is worse when you are HIV positive because there are
many things that can happen without [you] knowing, like
infections. (Participant #14)
The thing that made me decide to come here is because of
family planning. Then I found the Community Health Worker
talking down there in the family planning area and saying
how it is important to do a [HIV] test and to come to check
for herpes. Then I told myself to come and find out about
my health because it is not good if I do not know what is
going on with my health. (Participant #11)

Others noted that information on the trial was provided
to them at the time that they had approached public sector
clinics for STI treatment. These women were concerned
specifically about their sexual health and used participation
in the trial as a means to better understand the symptoms
that they had.
The reasons to participate in the trial are because I heard about
herpes and I used to have a rash in my vagina. Then I thought

Results
Reasons for participation in a clinical
trial of HIV prevention

the treatment maybe would help me. (Participant #12)

In order to begin understanding adherence in this trial,
women were asked about their reasons for participation. The
vast majority of participants first approached the clinic and
became involved in the trial in an attempt to get information
and to gain control of their health, regardless of the time
since their HIV diagnosis.

go and find out about my status. (Participant #16)

[I came to the clinic] to get information – I came to the
clinic to sort out my health. (Participant #15)

Working with women’s interest in their health, trial screening staff at the clinic encouraged women to investigate whether
they were infected with HSV-2 and HIV. A number of women
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The thing that made me decide to participate in the study
was I started to see symptoms that I did not understand, like
I had discharge and I was always sick so then I decided to

A further group of women joined the trial already aware
of the fact that they were either HIV or HSV-2 seropositive
(or both). They noted that participation in the trial gave them
the opportunity to better manage their illnesses and to obtain
additional information about infection, treatment, and the
prevention of transmission to others.
The first reason was that I wanted to check myself, what
is my health like and I wanted them to treat me because
I have herpes. Those were the reasons why I came to [clinic
name]. (Participant #8)
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The people from [clinic name] came to [local community]
and told us about the clinic so then I told myself that I must
come to the clinic to find out more about my health. Even
though I knew that I am HIV-positive but I wanted to know
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more about herpes. (Participant #25)

At the time of the trial, aciclovir was not available as
first-line therapy for genital ulcers in the South African public
health sector, and could only be obtained at considerable cost
through the private sector. Among those women who noted
that the potential for herpes treatment was a strong motivator
for participation, a small subset particularly noted that free
treatment had motivated their participation. Participant #4
noted: ‘… they said after finding out that you have this virus
they will give you free treatment.’
A strong motivator for trial participation among this
group of HIV-positive women was the ability, through the
trial procedures, to have monthly updates on their CD4 cell
count. At the time of the trial, antiretroviral treatment of HIV
was available free in the public health sector for patients
with CD4 cell count below 200. Women who had known
their HIV-positive status for more than 1 year were therefore
particularly interested in participating in the trial to obtain
more regular CD4 testing than would usually be available to
them in the public sector, and thereby increase their chance
of initiating HIV treatment as soon as they were eligible.
I have not been sick since I knew that I am HIV-positive but
I know that if you are HIV-positive you must always check
your CD4 count, you must not wait until your CD4 count
goes down. I think that is the thing that made me decide to
come and join the study even though they told me that they
are doing research but I wanted to see if they were going
to help me. (Participant #19)

Although women did discuss HIV and HSV-2 specifically
during the interviews, they were more likely to speak of wanting to improve their health more generally. This reflects that
women’s decisions to participate in this clinical trial were
made independently of their diagnosis and reflect an attempt
to address concerns with their health generally, rather than
being specifically focused on HSV-2 and aciclovir. Although
access to information and treatment dominated discussions,
a small number of women discussed other motivations for
trial participation, beyond access to improved health care.
The issue of receiving reimbursement was not a motivating factor for most women. In fact, only a single participant
noted that reimbursement had affected her decision to participate in the trial when she said that beyond the benefit of
having her CD4 cell count monitored: ‘I would say money
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also helped me in addition to the other things that I was getting here.’ (Participant #14). Indeed, if women did discuss the
issue of reimbursement, it was more likely to be in the context
of assuring the interviewer that money had not been part of
their motivation for joining the study. Participant #20 stated:
‘I joined the study because I wanted to know about my health,
it was not because of money.’ This type of statement was
echoed by a further participant.
My aim for coming to the clinic was to get something
to help me. I found what I was looking for because the
medication that I received helped with my problem. My aim
was not to receive money when I came here. If it was just
because I wanted money then it would have been better if
I had just stayed at home. (Participant #16)

Altruism was also not a major determining factor in
women’s trial participation. Most women displayed a good
understanding of the concepts of research trials, randomization, and placebo controls. The statement by Participant #19:
‘I was wishing to get the one that they said it is the active one.
Then I told myself that what about the nurse? She doesn’t
even know which one is going to work. So I thought whatever
I am going to get will be fine with me’ reflects the attitude of
most women in the trial. Women reported feeling certain that
whatever drug they received in the trial would assist them,
although they understood that randomization and placebo
drugs were a necessary component of the research process.
While this detailed understanding of the mechanisms
of randomized placebo-controlled trials might suggest that
women’s participation was motivated by altruism, only
a single participant explicitly noted that her decision to
participate was motivated by a desire to assist the research
process. She explained:
The thing they told us is that they don’t know if it is working
or not because they are still doing research, so I did not
have a problem if it is not working because I wanted to help
them to discover the information. (Participant #4)

Overall, women discussed their decisions to participate in
the research process as a rational health decision in the face of
general poor reproductive health in their local communities.
This is reflected by the fact that many of the women reported
having discussed the trial with family and friends when making their decision about participation.
My mother helped me to make the decision to come to the
clinic. She told me that I must go – maybe it’s where I am
going to get help, because I was starting to stress myself.
(Participant #6)

Patient Preference and Adherence 2012:6
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Women were most likely to have asked for opinions on
participation from female relatives or friends, and while
most reported that their partners were aware of their participation, few mentioned that their male partners had assisted
them in deciding to participate in the study. Additionally,
women specifically reported discussing trial participation
with friends or family they knew were infected with HIV or
HSV-2 in the hope that they too might make the decision to
participate in the study.
I did tell people about the study; like that they do HIV and
HSV-2 tests. The reason for me to tell them is that they
have sores and that problem with their vaginas. I also
told them that I used to have a sore in my vagina but
since I have enrolled in the study all the sores are gone.
(Participant #3)

There were some concerns about women being actively
dissuaded from trial participation given the stigma surrounding HIV in South African communities and a degree of mistrust of medical research based on historical exploitation by
the apartheid government and perceptions of profit motives
of large pharmaceutical companies. However, most women
interviewed here said that there were no individuals who
had attempted to stop them from participating in the trial,
although some noted that their partners had not supported
their decision to enroll.
Interviewer: Did you have a problem with other people
seeing you coming to the clinic?
Respondent: No, I did not think about that because you
know as a person you must not think about what other
people are going to say if they see you going to that clinic.
(Participant #8)

Given that women perceived participation in the trial
as an important and beneficial health intervention, most
reported that they ignored negative attitudes from partners.
Additionally, women did not appear to be concerned with
being identified as trial participants. Indeed, many specifically said that the trial was about their health and that they
would not have paid attention to anyone who had attempted
to sabotage their participation.

Adherence to trial visits
HIV prevention trials in general and this trial specifically,
have three adherence components. First, adherence to study
visits; second, adherence to the study drug (in this case
aciclovir or placebo); and third, adherence to particular
behavioral requirements.

Patient Preference and Adherence 2012:6
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Visit adherence is an important component of study drug
adherence because participants needed to visit the study
clinic every month in order to receive new drug supplies
and provide data on product adherence. During the trial,
adherence to clinic visits was considered good. Overall, more
than 90% of planned study visits were completed 541/604
(90%) in the aciclovir arm and 545/592 (92.1%) in the placebo arm. During post-trial qualitative interviews, one-third
of participants mentioned having missed scheduled visits,
although most noted that they had made up the visit within
the following week.
No reasons for missed visits emerged above all others;
problems with work, childcare, travel plans, and simply
forgetting were all mentioned.
Yes, I was supposed to come on Wednesday and then I did
not come on that day, I came on the next day because my
mother was not at home so there was no one to look after
my baby. (Participant #15)

Two women mentioned that they had missed their scheduled visits due to menstruation. This was, however, a protocol
requirement and was accommodated in the visit schedule. In
general, women noted that there were few good reasons for
missing clinic visits: visit schedules were known ahead of
time and required sufficient planning. Such planning included
having small children accompany them on study visits when
necessary, ensuring that they had transport money on the
day, and marking appointments on the calendar so that they
were not forgotten.
The strongest factor encouraging clinic visit adherence
was staff support. This was mentioned by more than half of
the interviewees and was often repeated multiple times in
individual interviews. Women consistently noted that the
clinic staff had been friendly, concerned, and had provided
guidance and assistance with problems beyond adherence
to the study.
I think it [staff attitude] helped me because when I thought
about coming to the clinic I knew that I am going to be
laughing and talking to people who care about me and
I loved to come to the clinic. (Participant #19)

Women commented on this particularly, given that they
were HIV-positive and seemed to expect some degree of poor
treatment from clinic staff, as illustrated by Participant #8
who noted that ‘They [clinic staff] helped me because they
managed to sit down with me and they said that this is not
the end of the world, you can continue with your life and
when I told them about my status they did not discriminate
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against me or talk negatively about me.’ In addition, study
staff assisted with adherence through reminder phone calls
and flexibility around study visits when participants had
scheduling conflicts.
As well as reminding participants about their medication,
family were also an important source of encouragement for
visit adherence, although this was discussed less frequently
than as motivation for product adherence.
My sister used to encourage me and remind me about my
date to come to the clinic … Everyone in my house used to
encourage me to come to my study visits. (Participant #6)

Discussion of barriers to visit adherence was relatively
limited, possibly as a result of the fact that women were
interviewed when they had completed all study visits. The
most significant barriers to participation were issues with
transport (8/31 interviewees), with women citing poor transport infrastructure and financial hardship as impediments to
visit adherence, although most managed to borrow money for
transportation costs knowing that they would be reimbursed
after each clinic visit.
The thing is I had to borrow money for transport so that
I can come to the clinic … when I get home I must pay the
money that I borrowed before I came to the clinic by using
the money from here. (Participant #17)
There was a transport problem because if I come here I must
change taxis twice so that is a problem … It is far, but there
is nothing that I can do about that. (Participant #23)

A further challenge that women perceived to their visit
adherence was waiting times at the clinic (5/31 interviewees),
despite this being vastly improved over normal waiting
times in public health clinics. A small number of women
also mentioned that their employment was a barrier to their
participation in the trial (this in connection with long waiting
times in the clinic). Most employed women were however
accommodated, where possible, through early morning
appointments and Saturday clinics.

Adherence to trial product
Pill counts were seen as a relatively objective means of
measuring adherence to study product between visits, and
adherence was calculated as the proportion of pills taken
out of the total number of pills that should have been taken
during the visit interval. Pill count measures provided a
useful estimate of average adherence each month, but relied
on participants to attend scheduled visits and to remember
to returned used pill packs and remaining pills. Pill pack
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return rates (ie, the proportion of pill packs returned to the
clinic out of those dispensed at the previous visit) were
similar when comparing the aciclovir group with the placebo
group at month 1 (96% vs 92%), month 2 (93% vs 96%),
and month 3 (94% vs 92%).
In this trial, levels of .90% adherence to the product
were desired. These levels of adherence were observed in
the early trials of aciclovir where suppression of .80%
of HSV-2 reactivation was achieved.12,13 It was thought
that similar levels of adherence would be required to see
an impact on HIV transmissibility. Using pill count as a
measure, overall adherence was high, with a mean adherence
rate of 95% in both study arms among those who returned
their pill boxes.
In addition to pill counts, adherence was also measured
by self-report. These complementary measures provided
additional information on the number of consecutive
doses (ie, one tablet twice a day) missed. HSV-2 has been
shown to resume reactivation after 5 days of stopping
HSV-2 suppressive therapy and so it was important to
know about the number of consecutive doses missed in
addition to an overall estimate of adherence by pill count.14
At each visit, participants were asked about missed doses
and reasons for this. Participants who reported missing 6 or
more consecutive days at each of the monthly visits were
considered to have lost any benefits of HSV-2 suppressive
therapy. Overall, slightly more participants in the placebo
arm compared to the aciclovir arm reported missing 6 or
more consecutive doses at all visits except the exit visit
(Table 1). The median number of doses reported as missed
at each month was also higher among the placebo group.
Forgetting to take pills, missing visits, and being away
from home were the three most frequently reported reasons
by women for missing doses in both treatment arms. Side
effects were seldom reported as a reason for omitting to
take drugs. Pill sharing was not reported as a reason for
missed pills by participants (Table 1), although in a specific
question about pill sharing, one participant who was in
the placebo arm reported at her month 3 visit that she had
shared ten pills with another person.
During the post-trial interview discussions about
adherence, almost half of participants mentioned that
they had missed some doses of their study drug. In most
instances, specific reasons for missed doses were not provided and the number of missed doses was not detailed. In
all cases, participants noted that they had missed ‘a couple
of doses’ and had used various strategies to make up missed
medication.
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Table 1 Self-reported adherence measures and reasons for
missed doses in the trial
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Aciclovir group
N = 151

Placebo group
N = 148

Missed six or more consecutive doses
Month 1
17 (11%)
15 (10%)
Month 2
11 (7%)
15 (10%)
Month 3
11 (7%)
15 (10%)
Median number of doses missed (IQR)
Month 1
6 (3–12)
4 (2–7)
Month 2
5 (2–8)
8 (3–16)
Month 3
3 (2–6)
16 (6–24)
Proportion of women reporting following reason for missing dosesa
Missed visit
Forgot
Away from home
Change in routine
Lost pills
Experienced side effects
Illness
Shared pills with
another person
Other reason

21 (14%)
44 (30%)
15 (10%)
2 (1%)
0
2 (1%)
3 (2%)
0

23 (16%)
32 (23%)
12 (8%)
6 (4%)
4 (3%)
1 (1%)
6 (4%)
0

1 (1%)

4 (3%)

Half of the interviewees specifically noted that they had
not missed any doses of study drug. There were no instances
in which the participant noted both and this therefore seems
an accurate representation of product adherence.
Yes, I did take my pills the way the way they told me to
do. Like they said I must take one in the morning and one
in the evening. So [name], the person who was working
at the pharmacy told me that it’s better if you take both at
the same time so I would not forget to take them … I never
missed to take my treatment and I never missed my clinic
visit. (Participant #15)

I forget to take my medication but not for such a long

A small number of interviewees explicitly linked their
motivation to adhere to study drugs to a perception that
their health had improved since enrolment in the study and
to ensuring that they experienced the health benefits they
believed would accrue through taking the correct dosage.
Participant #9 mentioned the following: ‘I think it’s because
I started to feel better and there were some changes so
I continued taking the pills.’ This concern with health benefits was reflected in participant comments about honesty
in reporting adherence to clinic staff. Participants reflected
that lying about their adherence would limit the degree to
which they could measure health improvements or manage
health problems.

time. It happened that I would not take my medication

I was honest because I wanted to know what was hap-

in the morning but I will take two in the evening.

pening to me if I forgot to take my pills or whether I have

(Participant #13)

improved or gotten worse [gained or lost something].

Note: This is a cumulative measure which represents the proportion of women
who cited a particular category as the reason for missed doses in a particular month,
summed over the 3-month period.
Abbreviation: IQR, interquartile range.
a

It was alright and then there were some days where

The reasons for drug non-adherence provided in the interviews closely matched self-reported information collected
quantitatively during the trial. In most instances participants
noted that a change in routine and traveling were reasons for
missed doses, as illustrated by Participant #20 who mentioned
that ‘… traveling was the thing that mostly disturbed me in
taking my pills.’ Other participants noted similar issues with
being away from home.
I used to have a problem with taking my pills because I used
to visit my boyfriend then I would often forget to take my
pills with me. (Participant #27)

A small number of participants mentioned that they
had experienced some negative health impacts that they
attributed to the study drugs. One participant noted that
the headaches she experienced during the trial prevented
her from taking all doses but other side effects attributed to
the study were minor and were not reported as impacting
on adherence.
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(Participant #16)
I think to lie is not good – it’s better you tell them the truth
even if you forgot to take your pills. Moreover when you
lie you are lying to yourself because if you did not take the
pills and then if hide this without telling the nurse it means
you are killing yourself. (Participant #19)

The study specifically examined whether pill sharing
might account for poor adherence. Among the participants
interviewed after the trial, no participants reported pill sharing and many noted that it was an unwise strategy if one
was concerned about one’s own health and that of partners,
family, or friends. Participant #14 noted: ‘I did not share with
anyone because if they give you some pills it is for you, not
for other people.’
Participants reported a range of strategies that assisted
them in maintaining adherence. Specifically, participants
reported taking missed doses in the evenings (as detailed
above) and particularly receiving support from family,
friends, partners, and clinic staff.
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I was honest because I told them [clinic staff] I was taking

use a condom when we have sex he listens to me and I also

my pills and I was honest about it. The other thing is that

take my pills nicely… The thing that helped me too much

I never missed to take my pills and my husband used to set

is to use a condom because I did not have any infections.

the alarm so the time it started to go off I knew it was the

When my husband wanted to have sex with me I said we

time for me to take my pills. (Participant #19)

must use a condom and before he used to say today we must

There were few instances in which participants mentioned
other strategies for adherence other than assistance from
family, partners, or clinic staff. One participant noted that she
made sure to always carry the medication with her in her bag
and another mentioned that she used her cell phone reminder
function as an alarm for her scheduled medication.

Adherence to trial behavioral
requirements
The trial protocol required that participants self-collect
vaginal tampons and refrain from vaginal practices such as
douching. Participants were also counseled about condom use
for general safe sex, but particularly for sex acts immediately
prior to study visits that might contaminate genital shedding
samples. Most women in the study were experienced tampon
users and most did not report douching prior to enrolment
in the trial. In instances where women did practice douching or other vaginal cleansing processes, the explanations
provided by study staff were viewed as sufficiently clear to
change their practices.
I did not have a problem about douching because they told
me that it is not good to insert your finger in your vagina.
(Participant #26)

Adhering to consistent condom use was the greatest
adherence challenge for women, although whether this was
in the context of general transmission prevention or to avoid
genital sample contamination was not detailed by participants.
Among those who struggled with adherence to condom use,
women indicated that partners suggested that condom use
implied a lack of trust, as illustrated by Participant #11 who
stated: ‘Yes I did have a problem with my partner – he did
not want to use condoms. When I asked him to use condoms,
he said it means I do not trust him, you see.’
In some instances women chose to frame discussions
of condom use within the requirements of the study and
being necessary for their health. These women appeared to
have some success with increasing condom use within their
partnerships.
Yes, it helped me because sometimes he [partner] would
want to have sex with me without using a condom. After
coming here it helped me because since I told him we must
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not use a condom. Then I would agree with him, because
I told myself that we are both HIV positive so it’s better
that we just finish ourselves. But after getting these pills
and when the sister explained to me, then I learned more
that you can prevent some of the things that will harm you.
(Participant #10)

Others noted that the information they received during study visits empowered them to make decisions about
their health and were therefore able to end relationships in
which partners remained unwilling to use condoms, such
as Participant #12 who indicated: ‘It was a problem, that is
why I stopped seeing him because he did not want to use
a condom, and he did not believe me, he was saying I am
telling him lies. I realized that if he does not want to use a
condom he is going to re-infect me so it’s better that we stop
seeing each other.’

Discussion and conclusion
This study confirms observations in the randomized, doubleblind, placebo-controlled trial that adherence to the study
visit schedule, study product, and protocol requirements
was generally very high. The measures used for recording
product adherence during the trial were complementary in
the information that they provided and were corroborated
during in-depth interviews with participants after the trial.
Ultimately, the outcomes observed in the trial confirm that
the adherence levels reported during the trial are likely to
be reliable.15
Evidence from the interviews reinforced the notion of
participant agency through using the trial to take control
of their health and to access optimal health care in a setting
of uncertain health care quality. This participation motivation explains the high levels of product adherence seen in
both arms of the study. Much has been written about the
poor quality of health care in the South African public
sector, specifically with regard to the attitude of health care
providers.16,17 Participants in this trial made use of the availability of well-trained and accessible staff to gain information
about their disease status and to effectively manage their HIV
prior to initiating antiretroviral therapy. Qualitative research
with women participating in other HIV prevention trials has
highlighted the importance of access to good quality health
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care and caring staff as motivators for trial participation,18,19
although this study is the first to tie these aspects to good
adherence.
Participation in clinical trials creates uncertainty through
the use of drugs with unknown efficacy or an inability to
determine whether one is receiving the active or placebo
drug.20 In this instance, women understood that they might
be receiving an inactive product, yet were willing to engage
with the trial nonetheless. Aciclovir for the suppression of
herpes was not available in the South African public health
sector at the time of this study and while participation may
have reflected a need to access long-term HSV-2 treatment,
participation in the trial went beyond access to a single drug.
Rather, participation was premised on access to good health
care in the context of HIV more generally.
Concerns that women would abuse reimbursements, fabricate data, share pills, or dump pills do not seem to have been
confirmed. Women appeared to have been honest about their
adherence limitations, particularly with regard to condom
use. Results may have been different had the trial targeted
primary HIV prevention, although barriers to condom use are
significant even with intensive safer sex counseling resources
allocated to clinical trials.21,22 While the negative influence
of partners on condom use should not be underestimated, in
this context, condom use adherence may not have resonated
with women’s desires for health promotion as much as the
potential to receive aciclovir for the management of their
herpes infection.
While the limited literature suggests that altruism and
compensation play a role in study participation,2,4,23 these
were not primary motivators in this case. Although the key
outcome of the trial was the prevention of HIV transmission
through limiting HIV shedding, no participants framed their
participation in an altruistic desire to prevent further HIV
transmission.
This study provides further evidence that good adherence
to daily medication is possible in low and middle income
countries characterized by poverty and social deprivation.
High levels of adherence have previously been demonstrated
for anti-retroviral use in South Africa,24 but this study indicates that high levels of drug adherence for non-life threatening diseases within the uncertainties of a clinical trial can also
be achieved when study activities are highly applicable to
participants or fill an unmet need. While there are additional
complexities associated with primary HIV prevention trials
in healthy volunteers, the results of this study bode well for
trials of pre-exposure prophylaxis (PrEP) in sub-Saharan
Africa. Additionally, the study highlights adherence as a
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multi-component issue extending beyond study product to
visits and behaviors associated with trial procedures. The
study indicates the additional value of conducting multiple
data collection procedures using different techniques for
data triangulation.

Limitations
Given that the qualitative component of the study was conducted at the completion of the main clinical trial, the study
may have excluded women who were lost to follow-up
in the main study and who may have experienced greater
barriers to participation. This influence is likely minimal
given than only 28 women missed their final month 3 visit
in the trial. Although not supported by the quantitative data
collected during the trial, there may have been some social
desirability bias to report higher levels of study adherence
than actually experienced. Attempts were made to minimize
this bias through conducting qualitative data collection at the
end of the trial and using different staff to those involved in
the collection of trial adherence data.
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